ClinicalTrials.gg
RecruitingNCT07489794MS-UI-PFMUpdated Mar 24, 2026

URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS

An observational study in Multiple Sclerosis and Urinary Incontinence (UI), sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
47
Ages
30 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 309 studies in Multiple Sclerosis with a site in Turkey — 60 open to participants now, 79 under way, 10 of them phase 3. Multiple Sclerosis · Turkey.

Planned enrollment
71st of 103
47 · median 60
Started
2026
with 43 others
Observational
103 of 309
27 open now
Primary completion
2026-09
later than 50 of 78 live
Registered
273rd of 309
by date

Among the 309 studies in Multiple Sclerosis with a site in Turkey, this one is the 71st largest by planned enrollment of the 103 observational ones that give a count, is one of 44 that started in 2026, is one of 103 observational ones, reaches primary completion later than 50 of the 78 other live ones, and was the 273rd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

60 of the 309 studies in Multiple Sclerosis with a site in Turkey are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 30 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Multiple Sclerosis with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to investigate the relationship between urinary incontinence severity and surface electromyography (EMG) findings in women with multiple sclerosis. It will also examine the association of urinary incontinence with disability, quality of life, physical activity, and fatigue.

Read the detailed description

This study investigates the relationship between urinary incontinence (UI) severity and pelvic floor muscle activity in women with multiple sclerosis (MS). UI is common in MS and negatively affects quality of life, physical activity, and social participation. The study also explores how UI severity is associated with disability, fatigue, and overall quality of life.

Participants' demographic and clinical information, including age, disease duration, MS type, and disability level (measured by the Expanded Disability Status Scale, EDSS), will be recorded. Standardized questionnaires will assess urinary symptoms, their impact on daily life, physical activity, and fatigue. Pelvic floor muscle activity will be evaluated using surface electromyography (EMG) with biofeedback, conducted by trained physiotherapists.

The study will be conducted at the Pelvic Floor Health Center and is planned as a cross-sectional study. All assessments, including questionnaires and EMG measurements, are expected to take approximately 45 minutes per participant. Findings from this study aim to improve understanding of UI in women with MS and guide future interventions.

03

Conditions studied

  • Multiple Sclerosis
  • Urinary Incontinence (UI)

Keywords

  • multiple sclerosis
  • urinary incontinence
  • Electromyography
  • Fatigue
  • Physical Activity
04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include female patients with multiple sclerosis (MS) aged 30-50 years, diagnosed according to the 2017 revised McDonald criteria, who experience urinary incontinence symptoms according to the International Continence Society (ICS) definition and have an EDSS score below 6.5. Participants must be able to communicate effectively. Patients who do not provide consent, have had a medication change within the last 6 months, are pregnant, have had a vaginal or cesarean delivery within the last 6 months, have pelvic organ prolapse, or have a urinary tract infection will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of multiple sclerosis (MS) according to the 2017 revised McDonald criteria.

Female patients aged 30-50 years (age range with higher prevalence of urinary incontinence in MS).

Experiencing urinary incontinence (UI) symptoms according to the International Continence Society (ICS) definition.

EDSS (Expanded Disability Status Scale) score below 6.5.

Patients with no communication difficulties. -

Exclusion criteria

Exclusion Criteria:

MS patients who do not provide consent to participate in the study.

MS patients who have had a medication change within the last 6 months.

Pregnant MS patients.

History of vaginal or cesarean delivery within the last 6 months.

Pelvic organ prolapse.

Urinary tract infection

-

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
47 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observational Group

    Participants will be observed for EMG activity, fatigue, physical activity, and urinary incontinence symptoms.

06

What researchers measure

Primary outcomes

  1. Pelvic floor muscle activity with surface EMG

    Evaluated using biofeedback-assisted surface EMG. Metrics recorded include mean EMG activity during contraction and rest phases, standard deviation of EMG activity, peak and minimum EMG values, contraction onset, and relaxation times

    Time frame: baseline

Secondary outcomes

  1. International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)

    Assesses severity and impact of urinary incontinence

    Time frame: baseline

  2. Incontinence Impact Questionnaire (IIQ-7)

    Evaluates the effect of urinary incontinence on quality of life

    Time frame: baseline

  3. International Physical Activity Questionnaire (IPAQ)

    Assesses participants' physical activity levels

    Time frame: baseline

  4. Fatigue Severity Scale (FSS)

    Measures severity of fatigue experienced by participants

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • Istanbul, Prof. Dr. Cemil Taşçıoğlu City Hospital, Turkey
    Istanbul, Turkey (Türkiye)
    Recruiting
    • Büşra Aydın Erkılıç, MSc · Contactbsrr.aydinn@gmail.com · 905062214052
    • Büşra Aydın Erkılıç, MSc · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) from this study will not be shared with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Sep 20, 2026
CompletionEst.
Oct 30, 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07489794
Lead sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Responsible party
Busra Aydin Erkilic (physiotherapist, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization) — Principal investigator
First posted
Mar 24, 2026
Start date
Mar 9, 2026
Primary completion
Sep 20, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Mar 24, 2026

Study contacts

Büşra Aydın Erkılıç, MSc
Contact
bsrr.aydinn@gmail.com
905062214052

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion